Capital Management Corp VA Reduces Stock Position in Harmony Biosciences Holdings, Inc. $HRMY

Capital Management Corp VA lowered its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 12.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 281,721 shares of the company’s stock after selling 41,191 shares during the quarter. Harmony Biosciences accounts for 1.7% of Capital Management Corp VA’s portfolio, making the stock its 25th largest position. Capital Management Corp VA’s holdings in Harmony Biosciences were worth $10,542,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its holdings in Harmony Biosciences by 6.9% in the third quarter. Dimensional Fund Advisors LP now owns 1,691,581 shares of the company’s stock worth $46,620,000 after purchasing an additional 109,405 shares during the last quarter. American Century Companies Inc. boosted its holdings in Harmony Biosciences by 11.2% in the third quarter. American Century Companies Inc. now owns 1,669,565 shares of the company’s stock worth $46,013,000 after purchasing an additional 168,145 shares during the last quarter. LSV Asset Management boosted its holdings in Harmony Biosciences by 7.1% in the third quarter. LSV Asset Management now owns 1,594,893 shares of the company’s stock worth $43,955,000 after purchasing an additional 106,391 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Harmony Biosciences by 42.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,295,381 shares of the company’s stock worth $35,701,000 after purchasing an additional 388,472 shares during the last quarter. Finally, SG Americas Securities LLC boosted its holdings in Harmony Biosciences by 4,102.4% in the fourth quarter. SG Americas Securities LLC now owns 961,667 shares of the company’s stock worth $35,986,000 after purchasing an additional 938,783 shares during the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Trading Up 1.8%

Shares of Harmony Biosciences stock opened at $31.83 on Friday. The company’s fifty day simple moving average is $28.76 and its 200-day simple moving average is $32.87. The stock has a market capitalization of $1.84 billion, a PE ratio of 11.75, a P/E/G ratio of 0.43 and a beta of 0.97. Harmony Biosciences Holdings, Inc. has a 1-year low of $25.52 and a 1-year high of $40.87. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.60 and a quick ratio of 3.58.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Tuesday, February 24th. The company reported $0.38 earnings per share for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.46). Harmony Biosciences had a net margin of 18.29% and a return on equity of 19.86%. The firm had revenue of $243.78 million for the quarter, compared to analysts’ expectations of $240.04 million. During the same quarter last year, the firm posted $0.85 EPS. The firm’s quarterly revenue was up 21.1% compared to the same quarter last year. As a group, equities analysts anticipate that Harmony Biosciences Holdings, Inc. will post 3.34 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Needham & Company LLC dropped their price target on shares of Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of Harmony Biosciences in a research note on Wednesday, February 25th. Weiss Ratings cut shares of Harmony Biosciences from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday. Truist Financial cut shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Finally, Mizuho set a $50.00 price target on shares of Harmony Biosciences in a research note on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $42.67.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial?stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.